secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2023-11-01T23:59:59+00:00
Accession:  0001213900-23-081941
Event type: leadership
Sentiment:  positive
Materiality: 0.65
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper appoints Thomas G. Wiggans as Chairperson; William Lis to retire in Dec 2023
--------------------------------------------------------------------------------

- Thomas G. Wiggans joins Board as Class II director and Chairperson effective Nov 1, 2023.
- Wiggans, 71, is former CEO/founder of Dermira (acquired by Lilly), ex-CEO of Pardes Biosciences.
- Wiggans receives option to purchase 110,000 shares, vesting over 4 years; larger than standard director grant.
- William Lis steps down as Chairperson immediately, will resign from Board on Dec 14, 2023 (no disagreement).
- Company focuses on briquilimab for mast cell diseases and LR-MDS; initial CSU study launching.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390023081941/0001213900-23-081941-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390023081941/ea187564-8k_jasper.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-081941

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer